Roland Walter, MD
Hematology · Seattle, WANPI 1124139738
Payments from drug & device makers
Across 337 payments — averaging $36,257 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$2.6M
- Bristol Myers Squibb$2.6M
- Pfizer$2.2M
- Janssen Research & Development, LLC$2M
- AbbVie$1.6M
- Amgen$419K
- plus $733K from 13 others
Across 2 payments — averaging $2273.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$4K
- Pfizer$780
What the payments were for
- Consulting fees$77,16684%
- Speaking & faculty fees$9,44410%
- Travel & lodging$3,3564%
- Food & beverage$2,2552%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 67 | $2,577,732 |
| Bristol Myers Squibb | 6 | $2,570,080 |
| Pfizer | 15 | $2,233,544 |
| Janssen Research & Development, LLC | 20 | $2,046,064 |
| AbbVie | 45 | $1,639,212 |
| Amgen | 30 | $418,990 |
| Aptevo Therapeutics Inc | 7 | $298,444 |
| Immunogen, Inc. | 5 | $261,262 |
| Macrogenics, Inc. | 90 | $110,180 |
| Agios Pharmaceuticals, Inc. | 19 | $14,684 |
| GSK | 7 | $13,650 |
| Janssen Global Services, LLC | 7 | $9,322 |
| Astellas Pharma US Inc | 6 | $5,507 |
| Stemline Therapeutics Inc. | 2 | $5,265 |
| E.r. Squibb & Sons, L.L.C. | 3 | $4,968 |
| Gilead(2 entities) | 2 | $3,140 |
| Syndax Pharmaceuticals, Inc. | 3 | $3,079 |
| Astrazeneca UK Limited | 2 | $1,938 |
| Genentech USA, Inc. | 1 | $1,650 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,218,711 in reported general payments places this provider in the 95th percentile of 43 hematology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Seattle
- Pamela BeckerSeattle$3.7M
- Mary-Elizabeth PercivalSeattle$2.3M
- Barbara KonkleSeattle$1.6M
- Sioban KeelSeattle$1.1M
- Jordan GauthierSeattle$718K
- Kleber Yotsumoto FertrinSeattle$633K
- Sandhya PanchSeattle$530K
- Laura Connelly SmithSeattle$383K
- Geoffrey HillSeattle$370K
- Terry GernsheimerSeattle$305K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.